SELLAS Life Sciences Gr Financials - Benzinga

SELLAS Life Sciences Group Inc

SLSNASDAQ

Trade with Public

Trade with Public

$11.61

-0.37-3.09%

al cierre: Sep 25, 5:00 PM EST

$11.63

0.01990.17%

After hour: 5:43 PM EST

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Comparar Opciones Informe de acciones

SELLAS Life Sciences Gr Financials

SELLAS Life Sciences Gr (SLS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
SELLAS Life Sciences Gr Q2 EPS $(0.05) Misses $(0.04) Estimate

SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. This is a 28.57 percent increase over losses of $(0.07) per share

Benzinga Newsdesk

PRO
SELLAS Life Sciences Gr Q1 EPS $(0.05) Beats $(0.06) Estimate

SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 28.57 percent increase over losses of $(0.07) per share

Benzinga Newsdesk

PRO
SELLAS Life Sciences Gr Q4 EPS $(0.05) Beats $(0.07) Estimate

SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 28.57 percent. This is a 37.5 percent increase over losses of $(0.08) per share

Benzinga Newsdesk

PRO
SELLAS Life Sciences Gr Q3 EPS $(0.06) Beats $(0.09) Estimate

SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.09) by 29.41 percent. This is a 40 percent increase over losses of $(0.10) per share

Benzinga Newsdesk

PRO
SELLAS Life Sciences Gr Q2 EPS $(0.07) Beats $(0.08) Estimate

SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 15.66 percent. This is a 46.15 percent increase over losses of $(0.13) per share

Benzinga Newsdesk

PRO
SELLAS Life Sciences Gr Q1 EPS $(0.07) Beats $(0.10) Estimate

SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 30 percent. This is a 66.67 percent increase over losses of $(0.21) per share

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved